Plain-English translation of NCT07635693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study is observing 20 multiple sclerosis patients who are receiving autologous hematopoietic stem cell transplantation (HSCT) as part of their standard care. The researchers want to understand how your immune system recovers after the transplant, particularly focusing on how a medication called ATLG (rabbit antithymocyte globulin) behaves in your body and how your immune cells come back. By carefully tracking these patterns, the study aims to gather information that will help design better future treatments.
Stem cell transplantation is an established treatment option for certain types of aggressive multiple sclerosis, but doctors don't yet fully understand how the immune system rebuilds after this procedure or how this medication works during that recovery phase. This study will help fill that knowledge gap and improve future treatment planning.
You likely qualify if…
You likely don't qualify if…
As a participant, you will receive your stem cell transplant according to standard medical protocols—this is not a new experimental procedure, but rather standard care being carefully monitored. The study involves observing your medical care, monitoring your blood work and immune markers at various timepoints, and tracking how your immune system recovers after the transplant. Your doctors will collect information about your health outcomes and how well the treatment works for your multiple sclerosis over time.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Italy